DexCom, Inc.
HealthcareNASDAQ:DXCM · NASDAQ Global Select
-$0.64 today
Vol 2.46M · Avg 5.41M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
30.5%
avg 6.3%
ROIC
16.6%
avg 0.1%
ROA
13.2%
avg 0.8%
Analysis
ROE is currently the strongest return metric at 30.5% versus its period average of 6.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kevin Ronald Sayer | Executive Chairman of the Board | $2.43M | — | 68 | $382,482.00 | 0.10% |
Jacob Steven Leach | President, CEO & Director | $2.05M | — | 48 | $5,565.00 | <0.01% |
Jereme Sylvain | Executive Vice President, Chief Financial Officer & Chief Accounting Officer | $1.14M | — | 46 | $151,841.00 | 0.04% |
Michael Brown | Executive Vice President & Chief Legal Officer | $1.10M | — | 56 | $108,053.00 | 0.03% |
Jon Coleman | Executive Vice President & Chief Commercial Officer | $1.01M | — | 62 | $95,450.00 | 0.02% |
Sadie Stern | Executive Vice President & Chief Human Resources Officer | $1.01M | — | 51 | $130,059.00 | 0.03% |
Donald Abbey | Executive Vice President of Global Business Services, Regulatory, Medical & Clinical Affairs | $766,800.00 | — | 59 | $216,088.00 | 0.06% |
Peter Simpson | Executive Vice President & Chief Technology Officer | $423,920.00 | — | — | — | — |
Girish Naganathan | Executive Vice President & Chief Technology Officer | $423,920.00 | — | 49 | $47,725.00 | 0.01% |
Matthew Dolan | Executive Vice President of Strategy & Corporate Development | — | — | 45 | $42,044.00 | 0.01% |
Keri Leone | Senior Director of Global Medical Science & Education | — | — | — | — | — |
Sean Christensen | Vice President of Finance and Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$1.00M
Sells
26
$5.66M
Net Sentiment
$4.66M
Net selling
Most Active
Brown Michael Jon
6 transactions
1–10 of 28
Analysis
Insiders reported 2 buys worth $1.00M and 26 sells worth $5.66M over the last 12 months. That adds up to net selling of $4.66M. Brown Michael Jon was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +59.1% | +22.3% (15yr)11 analysts |
| Net Income | N/A | N/A | N/A | N/A11 analysts |
| EBIT | N/A | N/A | N/A | N/A11 analysts |
Analysis
Recent growth has been strongest in Revenue at +59.1% over three years. Forward estimates point to Revenue at +22.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Teva Pharmaceutical Industries Limited
NYSE:TEVA
$39.80B
Biogen Inc.
NASDAQ:BIIB
$29.59B
Koninklijke Philips N.V.
NYSE:PHG
$25.66B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.31B
Waters Corporation
NYSE:WAT
$23.18B
Labcorp Holdings Inc.
NYSE:LH
$21.68B
STERIS plc
NYSE:STE
$20.30B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.15B
Smith & Nephew plc
NYSE:SNN
$12.97B
Insulet Corporation
NASDAQ:PODD
$10.37B
Who manages DXCM?
DexCom, Inc. (DXCM) lists 12 active executives. The top listed executive is Kevin Ronald Sayer, Executive Chairman of the Board.
Are DXCM insiders buying or selling?
Recent insider activity shows net selling of $54.26M.
Explore More
Continue the stock analysis
Jump to another research area for this company.